Paper Details

  1. Home
  2. Paper Details

A randomized prospective comparison of chemotherapy to total body irradiation as initial treatment for the indolent lymphoproliferative diseases.

Author: JacobsP, KingH S

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

A study of 108 patients with indolent lymphoproliferative diseases compared chlorambucil and prednisone (CP) chemotherapy to fractionated total body irradiation (TBI). Both treatments had similar complete remission rates (CR) and survival times. For the entire group, the CR rates were 59% for CP and 52% for TBI, with median survivals of 53 and 57 months, respectively. Similar results were observed within subgroups of chronic lymphocytic leukemia (CLL), well-differentiated lymphocytic lymphoma (WDLL), and follicular lymphoma (FL). These findings suggest that CP and TBI are equally effective initial treatment options for indolent lymphoproliferative diseases, regardless of the specific disease type.
Paper Details　
Original Abstract of the Article :
One hundred eight consecutive patients with indolent lymphoproliferative diseases were stratified into chronic lymphocytic leukemia (CLL), stage III and IV well-differentiated lymphocytic lymphoma (WDLL), and stage III and IV follicular lymphoma (FL). Within each stratum, patients were prospectively...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/3555650

データ提供：米国国立医学図書館（NLM）

Chemotherapy vs. Total Body Irradiation for Indolent Lymphoproliferative Diseases

This study compares the effectiveness of chemotherapy and total body irradiation (TBI) as initial treatment options for indolent lymphoproliferative diseases, a group of slow-growing cancers affecting the lymphatic system. Researchers conducted a randomized prospective trial to evaluate the complete response rates and survival times for both treatment regimens in patients with chronic lymphocytic leukemia (CLL), well-differentiated lymphocytic lymphoma (WDLL), and follicular lymphoma (FL).

Similar Effectiveness for Indolent Lymphoproliferative Diseases

The study found that both chemotherapy and TBI were equally effective in treating indolent lymphoproliferative diseases. There was no statistically significant difference in complete response rates or survival times between the two treatment groups, regardless of the specific type of lymphoma. These findings provide valuable insights into the management of these conditions and offer clinicians a range of treatment options.

Personalized Treatment Plans

The study highlights the importance of considering individual patient factors when choosing a treatment approach. While both chemotherapy and TBI were found to be effective, the optimal choice may vary depending on the specific type of lymphoma, patient characteristics, and overall health status. This research emphasizes the need for personalized treatment plans tailored to individual needs.

Dr.Camel's Conclusion

Just as a camel navigates through different terrains, this study shows that there are multiple paths to success in treating indolent lymphoproliferative diseases. The choice of treatment approach should be individualized, considering the patient's unique needs and the complexities of their condition. This research provides a solid foundation for informed decision-making in the management of these diseases.

Date :
  1. Date Completed 1987-07-07
  2. Date Revised 2021-02-16
Further Info :

Pubmed ID

3555650

DOI: Digital Object Identifier

S0006-4971(20)78540-X

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.